血清HMGB-1水平与2型糖尿病患者合并冠心病的相关性

Relations between serum high-mobility group box 1 levels and the presence of coronary artery disease in patients with type 2 diabetes

目的探讨血清高迁移率族蛋白1(HMGB-1)水平与2型糖尿病患者合并冠心病的相关性。方法本研究共纳入198例2型糖尿病患者,根据患者是否罹患冠心病将所有患者分为冠心病组(CAD组,n=73)及非冠心病组(非CAD组,n=125),采用酶联免疫吸附(ELISA)法测量患者血清的HMGB-1水平。结果有CAD组患者血清HMGB-1水平较无CAD组患者明显升高(P<0.01)。多变量Logistic回归分析显示高血清HMGB-1水平与2型糖尿病患者存在冠心病呈独立相关(优势比2.403,95%CI 1.401-4.163,P<0.01)。结论血清HMGB-1水平是预测2型糖尿病患者合并冠心病的独立危险因子,血清HMGB-1有望成为预测2型糖尿病患者发生冠心病风险的重要的血清生物学标记物。

Objective To explore the relations between serum high-mobility group box 1 （ HMGB-1 ） levels and the presence of coro-nary artery disease （CAD） in patients with type 2 diabetes （T2DM）. Methods A total of 198 patients with type 2 diabetes were en-rolled in this study. All the patients were classified as CAD-positive group（ n = 73 ）and CAD-negative group（ n = 125 ）. Serum HMGB-1 levels were determined by enzyme-linked immunosorbent assay （ELISA）. Results Serum HMGB-1 levels were significantly higher in CAD-positive patients than in CAD-negative patients（ n = 109 ）. Multivariate logistic regression demonstrated that higher HMGB-1 levels were independently associated with the presence of CAD in patients with T2DM （ OR = 2.403,95 % CI 1. 401 - 4.163, P 〈 0.01 ）. Conclusion Serum HMGB-1 is an independent risk factor for CAD in T2DM patients. These results suggest that HMGB-1 might be a useful biomarker for predicting the presence of CAD in patients with T2DM.